戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 in patients with myocardial hypoperfusion on noninvasive testing.
2 cted coronary artery disease (CAD) requiring noninvasive testing.
3  suspected coronary artery disease requiring noninvasive testing.
4 n quality of life than evaluation with usual noninvasive testing.
5 sis of heart failure cannot be determined by noninvasive testing.
6 heterization recommend a risk assessment and noninvasive testing.
7 emia, even in patients selected for abnormal noninvasive testing.
8 icity of symptoms and diagnostic accuracy of noninvasive testing.
9 es appear to obviate the need for subsequent noninvasive testing.
10 e, and extent of atherosclerosis detected by noninvasive testing.
11 nd 35.1% in 2014), and high-risk findings on noninvasive testing (22.2% in 2010 and 33.2% in 2014) (P
12 d population had low adherence to first-step noninvasive testing (45%), second-step follow-up colonos
13 tic patients with suspected CAD who required noninvasive testing, a strategy of initial CTA, as compa
14                                 Based on the noninvasive testing alone, 27% patients underwent surger
15 ed upon predefined risk factors, rather than noninvasive testing alone, was applied to a subgroup (20
16 icant cardioprotective effect as measured by noninvasive testing and clinical CHF.
17                                              Noninvasive testing and left ventricular ejection fracti
18 tients or patients with low-risk findings on noninvasive testing and minimal medical therapy are view
19 tients or patients with low-risk findings on noninvasive testing and minimal medical therapy were vie
20  exclusively among subjects first undergoing noninvasive testing and overall, was performed in only 1
21 ces and time trends in patients referred for noninvasive testing and subsequent use of invasive proce
22                    We determined patterns of noninvasive testing and the diagnostic yield of catheter
23 monitoring and staging, incorporating serial noninvasive testing and timely referral for liver transp
24 afe omission of the intensive care phase and noninvasive testing, and a day 3 hospital discharge stra
25 f medical therapy, risk level as assessed by noninvasive testing, and coronary anatomy.
26 f medical therapy, risk level as assessed by noninvasive testing, and coronary anatomy.
27 plaque composition and behavior, accuracy of noninvasive testing, and response to surgical and percut
28 on of coronary calcium by EBCT as an initial noninvasive testing approach minimized direct costs, and
29  catheterization and revascularization after noninvasive testing are not well defined.
30 t known coronary artery disease referred for noninvasive testing at 193 sites in North America.
31 essment with right heart catheterization and noninvasive testing at 3 to 6 months and annually therea
32 nosis in symptomatic patients often involves noninvasive testing before invasive coronary angiography
33                                              Noninvasive testing can help identify liver disease in s
34                    At present, the choice of noninvasive testing for a diagnosis of significant coron
35 he preceding year, who received nonemergent, noninvasive testing for CAD (n = 282,830).
36 tween Black and White individuals undergoing noninvasive testing for coronary artery disease is not k
37  coronary artery disease (CAD) often require noninvasive testing for diagnostic and prognostic evalua
38                                      Initial noninvasive testing for H. pylori has lower charges than
39                                              Noninvasive testing for Helicobacter pylori is widely av
40 y with biopsy should be performed only after noninvasive testing for infectious diarrhea and a thorou
41                         Guidelines recommend noninvasive testing for patients with stable chest pain,
42 the practicing clinician in the selection of noninvasive testing for stable chest pain.
43 perfusion therapy, risk level as assessed by noninvasive testing, fractional flow reserve testing, an
44                                     Overall, noninvasive testing had only a modest impact on clinical
45                         The increased use of noninvasive testing has also begun to challenge the role
46                                A hallmark of noninvasive testing has been the identification of patie
47                         However, the role of noninvasive testing has recently been challenged.
48 ce of compelling clinical evidence and after noninvasive testing has yielded negative findings.
49            Cardiac magnetic resonance (CMR), noninvasive testing, has been used in monitoring heart t
50 6% of stable, symptomatic patients requiring noninvasive testing have high-risk CAD.
51            Results of prospectively acquired noninvasive testing in 47 consecutive transplant recipie
52  downstream use of invasive procedures after noninvasive testing in community practice.
53 ity and dyspnea and highlight limitations of noninvasive testing in the identification of HFpEF.
54                               Further use of noninvasive testing, invasive procedures, medications, a
55                                              Noninvasive testing is best done in selected patients wh
56 new-onset acute heart failure (new-AHF) when noninvasive testing is impossible.
57                                   Therefore, noninvasive testing is recommended by relevant guideline
58                   The most important goal of noninvasive testing is to identify patients with left ma
59 use of coronary angiography without previous noninvasive testing is typically not advocated.
60 guidelines when demonstration of ischemia by noninvasive testing is unavailable.
61 egnant population in person with a rapid and noninvasive testing method may provide a practical model
62 rmation in combination with more traditional noninvasive testing methods.
63 re unit and day 3 hospital discharge without noninvasive testing [n = 237] or traditional care [n = 2
64                    Plasma cfDNA PCR offers a noninvasive testing option for early and accurate diagno
65                    Limited data exist on how noninvasive testing options compare for evaluating patie
66 re was no significant decrease in subsequent noninvasive testing or revascularization procedures.
67 st regarding the need for intensive care and noninvasive testing or the appropriate length of hospita
68 d positive predictive values to conventional noninvasive testing pathways across all prevalence subgr
69 ase do not have documentation of ischemia by noninvasive testing prior to elective PCI.
70  role of screening with serum biomarkers and noninvasive testing remains controversial, and in this r
71 individuals with a normal or mildly abnormal noninvasive testing result and the 54.3% (4559 of 8396)
72        Coronary angiography without previous noninvasive testing resulted in reasonable cost-effectiv
73                                              Noninvasive testing should improve accuracy in decision
74                 Thus, no currently available noninvasive testing strategy can reliably exclude DVT in
75  treadmill testing may emerge as the initial noninvasive testing strategy in elderly patients who are
76 ease in women, there is a need to identify a noninvasive testing strategy that is able to accurately
77 19 vs. $ 10,734; p < 0.0001), whereas in the noninvasive testing stratum, when the cost weight of FFR
78  to evaluate the prognostic value of routine noninvasive testing--stress thallium-201 imaging, rest t
79 spected coronary artery disease who required noninvasive testing, symptoms and QOL improved significa
80                                         This noninvasive testing technique is a valid indicator of po
81 ice the rate in the community; one-third had noninvasive testing that indicated advanced fibrosis or
82       Because patients may have had abnormal noninvasive testing that led to performance of coronary
83 NS: Among contemporary patients referred for noninvasive testing, the DF risk score overestimates the
84 l lung diseases provides the opportunity for noninvasive testing to establish an etiologic diagnosis,
85 he choice of either anatomical or functional noninvasive testing to evaluate suspected coronary arter
86         The decision about whether to obtain noninvasive testing to further define cardiovascular sta
87                                              Noninvasive testing using resting and posttreadmill exer
88                                              Noninvasive testing was infrequent and medical costs wer
89                                              Noninvasive testing was performed in 83.9% of the patien
90  history taking and physical examination and noninvasive testing were compared with screening recomme
91 isk factors, and symptoms and the results of noninvasive testing were correlated with the presence of
92 patients with stable chest pain referred for noninvasive testing will have normal coronary arteries a
93 e it may overcome some of the limitations of noninvasive testing, will clearly define high-risk patie
94 requires invasive specimen collection, while noninvasive testing with galactomannan is moderately acc
95 old, the most cost-effective option would be noninvasive testing with magnetic resonance elastography
96 servative, ischemia-guided strategy included noninvasive testing with radionuclide ventriculography a
97 " management, defined as medical therapy and noninvasive testing, with subsequent invasive management